“allergan” Archives

in
Entry Author Date Location
FDA Panel Vote Weighs in Favor of Alkermes Psych Drug, With Caveats 10/09/20 Europe
AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial 08/27/20 New York
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact 08/07/20 Boston
Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejection 06/26/20 National
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More 06/19/20 National
Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug 06/18/20 Seattle
Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs 06/18/20 San Diego
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes 06/11/20 Boston
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
AMAG Pharma Sells Off Women’s Health Product in Planned Divestment 05/22/20 Boston
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug 04/15/20 New York
Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study 03/30/20 National
Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data 03/09/20 Boston
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
Allergan Offloads Two Drugs to Secure Approval of Merger With AbbVie 01/27/20 National
Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More 01/03/20 National
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines 12/24/19 National
Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio 11/15/19 San Diego
$5.8B for Nothing: AbbVie Shelves Stemcentrx Drug After Latest Flop 08/29/19 Detroit Ann Arbor
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More 08/23/19 National
Bio Roundup: Zolgensma Fallout, Duchenne Redux, Ebola Boost & More 08/16/19 National
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
AbbVie to Pay $63B for Allergan to Prepare for Life Without Humira 06/25/19 Detroit Ann Arbor
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall 06/11/19 San Francisco
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments 05/03/19 National
Acelity Sells to 3M in Deal Valued at $6.7 Billion, Ending IPO Plan 05/02/19 Texas
Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More 04/19/19 National
Page 1 of 5 next page »